<DOC>
	<DOCNO>NCT01628640</DOCNO>
	<brief_summary>The primary purpose study evaluate safety viral agent call vesicular stomatitis virus use patient liver cancer . The study virus gene insert allow production interferon beta , substance dual function restrict spread virus tumor cell healthy liver cell also independent anti-cancer activity . Although primary goal study evaluate safety delivery viral agent people , patient may benefit clinically shrinkage stabilization tumor reduction cancer relate symptom ( e.g . pain ) . - Funding Source - FDA OOPD</brief_summary>
	<brief_title>Viral Therapy Treating Patient With Liver Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) vesicular stomatitis virus ( VSV ) -interferon beta ( IFN-beta ) ( recombinant vesicular stomatitis virus express interferon beta ) patient hepatocellular carcinoma ( HCC ) refractory intolerant sorafenib therapy . SECONDARY OBJECTIVES : I . To estimate tumor response rate overall survival . TERTIARY OBJECTIVES : I . To determine pharmacokinetic ( PK ) profile VSV-IFN-beta patient HCC measurement VSV-IFN-beta blood reverse transcriptase polymerase chain reaction ( RT-PCR ) . II . To characterize pharmacodynamics ( PD ) VSV-IFN-beta way measure serum interferon-beta also VSV-RT-PCR VSV-IFN-beta list . III . Assess CD8+ T cell ( general VSV-hIFN-beta specific ) natural killer ( NK ) cell response . IV . Assess status human interferon beta pathway pre/post therapy tumor/normal liver tissue ( status IFN-beta , interferon stimulate gene factor 3 [ ISGF3 complex constitute signal transducer activator transcription ( STAT ) 1/2 p48 ( ISGF3 Î³ ) ] ) . V. Assess phosphorylation STAT1/2 post-therapy . VI . Evaluate transcription interferon mediate gene ( protein kinase R , death receptor-tumor necrosis factor [ TNF ] -related apoptosis-inducing ligand [ TRAIL ] , 2'-5 ' oligoadenylate/ribonucleic acid [ RNA ] se L protein , heat shock protein [ Hsp 60/70/90 ] , major histocompatibility class antigens interferon regulatory factor [ IRF ] -7 ) . VII . Assess presence VSV tumor/normal liver subsequent administration VSV-human IFN-beta ( hIFN- beta ) . OUTLINE : This dose-escalation study . Patients receive recombinant vesicular stomatitis virus express interferon beta intratumorally day 1 . After completion study treatment , patient follow every 4 week 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>Histologically cytologically confirm hepatocellular carcinoma refractory intolerant sorafenib base therapy Absolute neutrophil count ( ANC ) &gt; = 1000/mm^3 Platelet count &gt; = 80,000/mm^3 Hemoglobin &gt; = 10 g/dl Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) = &lt; 5 x ULN Creatinine = &lt; 1.5 x ULN Total bilirubin = &lt; 3 x ULN International normalize ratio ( INR ) = &lt; 1.5 x ULN Activated partial thromboplastin time ( aPTT ) = &lt; 1.5 x ULN Ability provide inform write consent Willingness return Mayo Clinic Arizona followup Life expectancy &gt; = 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Willingness provide biological specimen require protocol Negative serum pregnancy test = &lt; 7 day prior registration woman childbearing potential Child Pugh Score A B7 The patient partner agree use barrier method contraception study 4 month follow end active treatment Uncontrolled infection Systemic anticancer therapy = &lt; 4 week prior registration Known human immunodeficiency virus ( HIV ) infection Other concurrent chemotherapy , immunotherapy , radiotherapy , investigational therapy Pregnant nursing woman History bone marrow solid organ transplantation Patient surgical resection liver transplantation would appropriate Any condition , opinion investigator would render patient unsuitable participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>